SCHEMBL55048

SCHEMBL55048

CC(O)[C@H](C)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55047 1.00
SCHEMBL791249 1.00
SCHEMBL1041254 1.00
SCHEMBL2107037 1.00
SCHEMBL2932270 1.00
SCHEMBL5549445 1.00
SCHEMBL3518225 1.00
SCHEMBL2687210 1.00
Ammonia Solution, Strong SCHEMBL2340361 0.97
SCHEMBL28118146 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037354-B2 Cyclic pantetheine derivatives and uses thereof VECTIVBIO COMET AG (CH) 2024-07-16 US disclosed
US-20230218578-A1 BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-07-13 US disclosed
US-20230107216-A1 PANTETHEINE DERIVATIVES AND USES THEREOF VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) 2023-04-06 US disclosed
US-20230072313-A1 CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) 2023-03-09 US disclosed
EP-3887381-A2 CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF Comet Therapeutics, Inc. (US) 2021-10-06 EP disclosed
WO-2020113213-A2 CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF COMET THERAPEUTICS, INC. (US) 2020-06-04 WO disclosed
US-9777301-B2 Method for producing optically active amine compounds by deracemization INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2017-10-03 US disclosed
US-20160289715-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUNDS BY DERACEMIZATION INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2016-10-06 US disclosed
US-20160168204-A1 METHOD FOR PURIFYING OLIGOSACCHARIDE PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-06-16 US disclosed
US-20160017015-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-21 US disclosed
EP-1315732-B1 RADICICOL AND MONOCILLIN AND THEIR ANALOGUES AND USES THEREOF SLOAN KETTERING INST CANCER (US) 2006-06-07 EP disclosed
WO-2006009789-A2 ARYL-SUBSTITUTED PIPERAZINE DERIVATIVES NEUROGEN CORPORATION (US) 2006-01-26 WO disclosed
US-20060009456-A1 Aryl-substituted piperazine derivatives NEUROGEN CORPORATION 2006-01-12 US disclosed
US-20020091151-A1 Novel macrocycles and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2002-07-11 US disclosed
EP-1077970-A1 11-ARYL-BENZO(B)NAPHTHO(2,3-D)FURANS AND 11-ARYL-BENZO(B)NAPHTHO(2,3-D)THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
US-6110962-A FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-08-29 US disclosed
WO-1999058521-A1 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
US-5145957-A Carbapenicillin intermediates MERCK & CO., INC. (US) 1992-09-08 US disclosed
EP-0333268-A1 Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone MERCK & CO. INC. (US) 1989-09-20 EP disclosed
US-4778883-A 3-(CHFCH3)-azetidinone intermediates SANRAKU INCORPORATED (JP) 1988-10-18 US disclosed